@article {Cox:2018:1027-3719:407,
title = "Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis",
journal = "The International Journal of Tuberculosis and Lung Disease",
parent_itemid = "infobike://iuatld/ijtld",
publishercode ="iuatld",
year = "2018",
volume = "22",
number = "4",
publication date ="2018-04-01T00:00:00",
pages = "407-412",
itemtype = "ARTICLE",
issn = "1027-3719",
eissn = "1815-7920",
url = "https://www.ingentaconnect.com/content/iuatld/ijtld/2018/00000022/00000004/art00011",
doi = "doi:10.5588/ijtld.17.0706",
keyword = "delamanid, global use, drug-resistant TB, bedaquiline",
author = "Cox, V. and Brigden, G. and Crespo, R. H. and Lessem, E. and Lynch, S. and Rich, M. L. and Waning, B. and Furin, J.",
abstract = "SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of
these drugs in their treatment regimens.DESIGN: A convenience sample of 36 countries voluntarily reported monthly data on cumulative programmatic use of new drugs to the Drug-Resistant TB Scale-Up Treatment Action Team between 1 July 2015 and 31 June 2017. Programmatic use was defined
as treatment for MDR-TB with newer drugs outside of clinical trials or compassionate use.RESULTS: A total of 10164 persons were started on BDQ and 688 started on DLM during the reporting period. Only 15.7% of the 69213 persons estimated to need newer drugs over the study
period were reported to have received them.CONCLUSION: While there has been significant progress in some countries, uptake of the newer drugs has not kept pace with a conservative estimate of need; fewer than 20% of persons likely to benefit from either BDQ or DLM have received them. Concerted
efforts are needed to ensure that the newer drugs are made available more widely for persons with MDR-TB in need of these therapeutic options.",
}